Literature DB >> 17592142

Chymotrypsin C (caldecrin) promotes degradation of human cationic trypsin: identity with Rinderknecht's enzyme Y.

Richárd Szmola1, Miklós Sahin-Tóth.   

Abstract

Digestive trypsins undergo proteolytic breakdown during their transit in the human alimentary tract, which has been assumed to occur through trypsin-mediated cleavages, termed autolysis. Autolysis was also postulated to play a protective role against pancreatitis by eliminating prematurely activated intrapancreatic trypsin. However, autolysis of human cationic trypsin is very slow in vitro, which is inconsistent with the documented intestinal trypsin degradation or a putative protective role. Here we report that degradation of human cationic trypsin is triggered by chymotrypsin C, which selectively cleaves the Leu(81)-Glu(82) peptide bond within the Ca(2+) binding loop. Further degradation and inactivation of cationic trypsin is then achieved through tryptic cleavage of the Arg(122)-Val(123) peptide bond. Consequently, mutation of either Leu(81) or Arg(122) blocks chymotrypsin C-mediated trypsin degradation. Calcium affords protection against chymotrypsin C-mediated cleavage, with complete stabilization observed at 1 mM concentration. Chymotrypsin C is highly specific in promoting trypsin degradation, because chymotrypsin B1, chymotrypsin B2, elastase 2A, elastase 3A, or elastase 3B are ineffective. Chymotrypsin C also rapidly degrades all three human trypsinogen isoforms and appears identical to enzyme Y, the enigmatic trypsinogen-degrading activity described by Heinrich Rinderknecht in 1988. Taken together with previous observations, the results identify chymotrypsin C as a key regulator of activation and degradation of cationic trypsin. Thus, in the high Ca(2+) environment of the duodenum, chymotrypsin C facilitates trypsinogen activation, whereas in the lower intestines, chymotrypsin C promotes trypsin degradation as a function of decreasing luminal Ca(2+) concentrations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17592142      PMCID: PMC2040881          DOI: 10.1073/pnas.0703714104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Gain-of-function mutations associated with hereditary pancreatitis enhance autoactivation of human cationic trypsinogen.

Authors:  M Sahin-Tóth; M Tóth
Journal:  Biochem Biophys Res Commun       Date:  2000-11-19       Impact factor: 3.575

2.  Trypsin activity is not involved in premature, intrapancreatic trypsinogen activation.

Authors:  Walter Halangk; Burkhard Krüger; Manuel Ruthenbürger; Jörg Stürzebecher; Elke Albrecht; Hans Lippert; Markus M Lerch
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2002-02       Impact factor: 4.052

3.  Human cationic trypsinogen. Arg(117) is the reactive site of an inhibitory surface loop that controls spontaneous zymogen activation.

Authors:  Zoltán Kukor; Miklós Tóth; Gábor Pál; Miklós Sahin-Tóth
Journal:  J Biol Chem       Date:  2001-12-17       Impact factor: 5.157

4.  Comparative in vitro studies on native and recombinant human cationic trypsins. Cathepsin B is a possible pathological activator of trypsinogen in pancreatitis.

Authors:  L Szilágyi; E Kénesi; G Katona; G Kaslik; G Juhász; L Gráf
Journal:  J Biol Chem       Date:  2001-04-18       Impact factor: 5.157

5.  Structural determinants of the half-life and cleavage site preference in the autolytic inactivation of chymotrypsin.

Authors:  A Bódi; G Kaslik; I Venekei; L Gráf
Journal:  Eur J Biochem       Date:  2001-12

6.  Human anionic trypsinogen: properties of autocatalytic activation and degradation and implications in pancreatic diseases.

Authors:  Zoltán Kukor; Miklós Tóth; Miklós Sahin-Tóth
Journal:  Eur J Biochem       Date:  2003-05

7.  Trypsinogen variants in pancreatic juice of healthy volunteers, chronic alcoholics, and patients with pancreatitis and cancer of the pancreas.

Authors:  H Rinderknecht; I G Renner; C Carmack
Journal:  Gut       Date:  1979-10       Impact factor: 23.059

8.  Two human trypsinogens. Purification, molecular properties, and N-terminal sequences.

Authors:  O Guy; D Lombardo; D C Bartelt; J Amic; C Figarella
Journal:  Biochemistry       Date:  1978-05-02       Impact factor: 3.162

9.  Characterization of human exocrine pancreatic proteins by two-dimensional isoelectric focusing/sodium dodecyl sulfate gel electrophoresis.

Authors:  G Scheele; D Bartelt; W Bieger
Journal:  Gastroenterology       Date:  1981-03       Impact factor: 22.682

Review 10.  Mechanisms of intestinal calcium absorption.

Authors:  Felix Bronner
Journal:  J Cell Biochem       Date:  2003-02-01       Impact factor: 4.429

View more
  54 in total

1.  Uncertainties in the classification of human cationic trypsinogen (PRSS1) variants as hereditary pancreatitis-associated mutations.

Authors:  Richárd Szmola; Miklós Sahin-Tóth
Journal:  J Med Genet       Date:  2010-05       Impact factor: 6.318

Review 2.  Chymotrypsin C mutations in chronic pancreatitis.

Authors:  Jiayi Zhou; Miklós Sahin-Tóth
Journal:  J Gastroenterol Hepatol       Date:  2011-08       Impact factor: 4.029

3.  High affinity small protein inhibitors of human chymotrypsin C (CTRC) selected by phage display reveal unusual preference for P4' acidic residues.

Authors:  András Szabó; Dávid Héja; Dávid Szakács; Katalin Zboray; Katalin A Kékesi; Evette S Radisky; Miklós Sahin-Tóth; Gábor Pál
Journal:  J Biol Chem       Date:  2011-04-22       Impact factor: 5.157

4.  Preimplantation factor (PIF) analog prevents type I diabetes mellitus (TIDM) development by preserving pancreatic function in NOD mice.

Authors:  Lola Weiss; Steve Bernstein; Richard Jones; Ravi Amunugama; David Krizman; Lellean Jebailey; Osnat Almogi-Hazan; Osnat Hazan; Zhanna Yekhtin; Janna Yachtin; Reut Shiner; Israel Reibstein; Elizabeth Triche; Shimon Slavin; Reuven Or; Eytan R Barnea
Journal:  Endocrine       Date:  2011-03-22       Impact factor: 3.633

5.  Increased activation of hereditary pancreatitis-associated human cationic trypsinogen mutants in presence of chymotrypsin C.

Authors:  András Szabó; Miklós Sahin-Tóth
Journal:  J Biol Chem       Date:  2012-04-26       Impact factor: 5.157

6.  Chymotrypsin C is a co-activator of human pancreatic procarboxypeptidases A1 and A2.

Authors:  Richárd Szmola; Melinda Bence; Andrea Carpentieri; András Szabó; Catherine E Costello; John Samuelson; Miklós Sahin-Tóth
Journal:  J Biol Chem       Date:  2010-11-22       Impact factor: 5.157

7.  Complex Formation of Human Proelastases with Procarboxypeptidases A1 and A2.

Authors:  András Szabó; Claudia Pilsak; Melinda Bence; Heiko Witt; Miklós Sahin-Tóth
Journal:  J Biol Chem       Date:  2016-06-29       Impact factor: 5.157

8.  Determinants of chymotrypsin C cleavage specificity in the calcium-binding loop of human cationic trypsinogen.

Authors:  András Szabó; Miklós Sahin-Tóth
Journal:  FEBS J       Date:  2012-10-30       Impact factor: 5.542

9.  Functional effects of 13 rare PRSS1 variants presumed to cause chronic pancreatitis.

Authors:  Andrea Schnúr; Sebastian Beer; Heiko Witt; Péter Hegyi; Miklós Sahin-Tóth
Journal:  Gut       Date:  2013-03-01       Impact factor: 23.059

10.  Pancreatitis-associated chymotrypsinogen C (CTRC) mutant elicits endoplasmic reticulum stress in pancreatic acinar cells.

Authors:  Richárd Szmola; Miklós Sahin-Tóth
Journal:  Gut       Date:  2009-11-30       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.